Global Parkinson's Disease Drugs Market

Parkinson's Disease Drugs Comprehensive Study by Type (Carbidopa/Levodopa, Dopamine Receptor Agonists, MAO-Inhibitors), Route of Administration (Oral, Injection, Transdermal), End-users (Hospitals, Clinics, Others), Distribution Channel (Hospital, Online, Retail Pharmacies) Players and Region - Global Market Outlook to 2026

Parkinson's Disease Drugs Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Parkinson's Disease Drugs Market?

According to the American Association of Neurological Surgeons, in the United States, around 60,000 new cases of Parkinson’s disease are diagnosed each year and one to 1.5 million Americans currently have the disease. Parkinson's disease is a progressive nervous system disorder caused by degeneration of nerve cells in the part of the brain called the substantia nigra that affects movement. Recent studies have shown that symptoms of Parkinson's develop in patients with an 80 percent or greater loss of dopamine-producing cells in the substantia nigra. There is currently no cure for the disease, but treatment can help to relieve the symptoms and maintain the patient's quality of life.

The market study is being classified by Type (Carbidopa/Levodopa, Dopamine Receptor Agonists and MAO-Inhibitors) and major geographies with country level break-up.

AbbVie (United States, Merck (United States), Boehringer Ingelheim (Germany), Teva (Israel), Novartis AG (Switzerland), GSK (United Kingdom), Impax Laboratories (United States), Lundbeck (Denmark), UCB (Belgium), Valeant Pharmaceuticals (Canada), Acadia (United States), Sun Pharma (India), Wockhardt (India), Dr. Reddy’s (India), Intas (India), US WorldMeds (United States), Zydus Cadila (India) and Cipla (India) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Strides (India), 1 A Pharma (India) and Upsher-Smith (United States).

The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Parkinson's Disease Drugs market throughout the predicted period.

Segment Analysis
Analyst at AMA have segmented the market study of Global Parkinson's Disease Drugs market by Type, Application and Region.

On the basis of geography, the market of Parkinson's Disease Drugs has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Increasing Prevalence of Parkinson's Disease among Elderly People
  • High Demand for Effective Treatment for Parkinson's Disease

Market Trend
  • Increased Research and Development Activities
  • Rise in the Number of Diagnostic Centres

Restraints
  • No Complete Cure of Parkinson's Disease Available

Opportunities
  • Growth in the Geriatric Population Worldwide
  • Growth in the Healthcare Sector

Challenges
  • Stringent Government Rules and Regulations





Key Target Audience
Parkinson's Disease Drugs Manufacturers, Raw Material Suppliers, Distributors, Emerging Companies, Research Professionals and End-users

Report Objectives / Segmentation Covered

By Type
  • Carbidopa/Levodopa
  • Dopamine Receptor Agonists
  • MAO-Inhibitors
By Route of Administration
  • Oral
  • Injection
  • Transdermal

By End-users
  • Hospitals
  • Clinics
  • Others

By Distribution Channel
  • Hospital
  • Online
  • Retail Pharmacies

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Prevalence of Parkinson's Disease among Elderly People
      • 3.2.2. High Demand for Effective Treatment for Parkinson's Disease
    • 3.3. Market Challenges
      • 3.3.1. Stringent Government Rules and Regulations
    • 3.4. Market Trends
      • 3.4.1. Increased Research and Development Activities
      • 3.4.2. Rise in the Number of Diagnostic Centres
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Parkinson's Disease Drugs, by Type, Route of Administration, End-users, Distribution Channel and Region (value, volume and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Parkinson's Disease Drugs (Value)
      • 5.2.1. Global Parkinson's Disease Drugs by: Type (Value)
        • 5.2.1.1. Carbidopa/Levodopa
        • 5.2.1.2. Dopamine Receptor Agonists
        • 5.2.1.3. MAO-Inhibitors
      • 5.2.2. Global Parkinson's Disease Drugs by: Route of Administration (Value)
        • 5.2.2.1. Oral
        • 5.2.2.2. Injection
        • 5.2.2.3. Transdermal
      • 5.2.3. Global Parkinson's Disease Drugs by: End-users (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Clinics
        • 5.2.3.3. Others
      • 5.2.4. Global Parkinson's Disease Drugs by: Distribution Channel (Value)
        • 5.2.4.1. Hospital
        • 5.2.4.2. Online
        • 5.2.4.3. Retail Pharmacies
      • 5.2.5. Global Parkinson's Disease Drugs Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Parkinson's Disease Drugs (Volume)
      • 5.3.1. Global Parkinson's Disease Drugs by: Type (Volume)
        • 5.3.1.1. Carbidopa/Levodopa
        • 5.3.1.2. Dopamine Receptor Agonists
        • 5.3.1.3. MAO-Inhibitors
      • 5.3.2. Global Parkinson's Disease Drugs by: Route of Administration (Volume)
        • 5.3.2.1. Oral
        • 5.3.2.2. Injection
        • 5.3.2.3. Transdermal
      • 5.3.3. Global Parkinson's Disease Drugs by: End-users (Volume)
        • 5.3.3.1. Hospitals
        • 5.3.3.2. Clinics
        • 5.3.3.3. Others
      • 5.3.4. Global Parkinson's Disease Drugs by: Distribution Channel (Volume)
        • 5.3.4.1. Hospital
        • 5.3.4.2. Online
        • 5.3.4.3. Retail Pharmacies
      • 5.3.5. Global Parkinson's Disease Drugs Region
        • 5.3.5.1. South America
          • 5.3.5.1.1. Brazil
          • 5.3.5.1.2. Argentina
          • 5.3.5.1.3. Rest of South America
        • 5.3.5.2. Asia Pacific
          • 5.3.5.2.1. China
          • 5.3.5.2.2. Japan
          • 5.3.5.2.3. India
          • 5.3.5.2.4. South Korea
          • 5.3.5.2.5. Taiwan
          • 5.3.5.2.6. Australia
          • 5.3.5.2.7. Rest of Asia-Pacific
        • 5.3.5.3. Europe
          • 5.3.5.3.1. Germany
          • 5.3.5.3.2. France
          • 5.3.5.3.3. Italy
          • 5.3.5.3.4. United Kingdom
          • 5.3.5.3.5. Netherlands
          • 5.3.5.3.6. Rest of Europe
        • 5.3.5.4. MEA
          • 5.3.5.4.1. Middle East
          • 5.3.5.4.2. Africa
        • 5.3.5.5. North America
          • 5.3.5.5.1. United States
          • 5.3.5.5.2. Canada
          • 5.3.5.5.3. Mexico
    • 5.4. Global Parkinson's Disease Drugs (Price)
      • 5.4.1. Global Parkinson's Disease Drugs by: Type (Price)
  • 6. Parkinson's Disease Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. AbbVie (United States
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Merck (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Boehringer Ingelheim (Germany)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Teva (Israel)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Novartis AG (Switzerland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. GSK (United Kingdom)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Impax Laboratories (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Lundbeck (Denmark)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. UCB (Belgium)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Valeant Pharmaceuticals (Canada)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Acadia (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Sun Pharma (India)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. Wockhardt (India)
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
      • 6.4.14. Dr. Reddy’s (India)
        • 6.4.14.1. Business Overview
        • 6.4.14.2. Products/Services Offerings
        • 6.4.14.3. Financial Analysis
        • 6.4.14.4. SWOT Analysis
      • 6.4.15. Intas (India)
        • 6.4.15.1. Business Overview
        • 6.4.15.2. Products/Services Offerings
        • 6.4.15.3. Financial Analysis
        • 6.4.15.4. SWOT Analysis
      • 6.4.16. US WorldMeds (United States)
        • 6.4.16.1. Business Overview
        • 6.4.16.2. Products/Services Offerings
        • 6.4.16.3. Financial Analysis
        • 6.4.16.4. SWOT Analysis
      • 6.4.17. Zydus Cadila (India)
        • 6.4.17.1. Business Overview
        • 6.4.17.2. Products/Services Offerings
        • 6.4.17.3. Financial Analysis
        • 6.4.17.4. SWOT Analysis
      • 6.4.18. Cipla (India)
        • 6.4.18.1. Business Overview
        • 6.4.18.2. Products/Services Offerings
        • 6.4.18.3. Financial Analysis
        • 6.4.18.4. SWOT Analysis
  • 7. Global Parkinson's Disease Drugs Sale, by Type, Route of Administration, End-users, Distribution Channel and Region (value, volume and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Parkinson's Disease Drugs (Value)
      • 7.2.1. Global Parkinson's Disease Drugs by: Type (Value)
        • 7.2.1.1. Carbidopa/Levodopa
        • 7.2.1.2. Dopamine Receptor Agonists
        • 7.2.1.3. MAO-Inhibitors
      • 7.2.2. Global Parkinson's Disease Drugs by: Route of Administration (Value)
        • 7.2.2.1. Oral
        • 7.2.2.2. Injection
        • 7.2.2.3. Transdermal
      • 7.2.3. Global Parkinson's Disease Drugs by: End-users (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Clinics
        • 7.2.3.3. Others
      • 7.2.4. Global Parkinson's Disease Drugs by: Distribution Channel (Value)
        • 7.2.4.1. Hospital
        • 7.2.4.2. Online
        • 7.2.4.3. Retail Pharmacies
      • 7.2.5. Global Parkinson's Disease Drugs Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Parkinson's Disease Drugs (Volume)
      • 7.3.1. Global Parkinson's Disease Drugs by: Type (Volume)
        • 7.3.1.1. Carbidopa/Levodopa
        • 7.3.1.2. Dopamine Receptor Agonists
        • 7.3.1.3. MAO-Inhibitors
      • 7.3.2. Global Parkinson's Disease Drugs by: Route of Administration (Volume)
        • 7.3.2.1. Oral
        • 7.3.2.2. Injection
        • 7.3.2.3. Transdermal
      • 7.3.3. Global Parkinson's Disease Drugs by: End-users (Volume)
        • 7.3.3.1. Hospitals
        • 7.3.3.2. Clinics
        • 7.3.3.3. Others
      • 7.3.4. Global Parkinson's Disease Drugs by: Distribution Channel (Volume)
        • 7.3.4.1. Hospital
        • 7.3.4.2. Online
        • 7.3.4.3. Retail Pharmacies
      • 7.3.5. Global Parkinson's Disease Drugs Region
        • 7.3.5.1. South America
          • 7.3.5.1.1. Brazil
          • 7.3.5.1.2. Argentina
          • 7.3.5.1.3. Rest of South America
        • 7.3.5.2. Asia Pacific
          • 7.3.5.2.1. China
          • 7.3.5.2.2. Japan
          • 7.3.5.2.3. India
          • 7.3.5.2.4. South Korea
          • 7.3.5.2.5. Taiwan
          • 7.3.5.2.6. Australia
          • 7.3.5.2.7. Rest of Asia-Pacific
        • 7.3.5.3. Europe
          • 7.3.5.3.1. Germany
          • 7.3.5.3.2. France
          • 7.3.5.3.3. Italy
          • 7.3.5.3.4. United Kingdom
          • 7.3.5.3.5. Netherlands
          • 7.3.5.3.6. Rest of Europe
        • 7.3.5.4. MEA
          • 7.3.5.4.1. Middle East
          • 7.3.5.4.2. Africa
        • 7.3.5.5. North America
          • 7.3.5.5.1. United States
          • 7.3.5.5.2. Canada
          • 7.3.5.5.3. Mexico
    • 7.4. Global Parkinson's Disease Drugs (Price)
      • 7.4.1. Global Parkinson's Disease Drugs by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Parkinson's Disease Drugs: by Type(USD Million)
  • Table 2. Parkinson's Disease Drugs Carbidopa/Levodopa , by Region USD Million (2015-2020)
  • Table 3. Parkinson's Disease Drugs Dopamine Receptor Agonists , by Region USD Million (2015-2020)
  • Table 4. Parkinson's Disease Drugs MAO-Inhibitors , by Region USD Million (2015-2020)
  • Table 5. Parkinson's Disease Drugs: by Route of Administration(USD Million)
  • Table 6. Parkinson's Disease Drugs Oral , by Region USD Million (2015-2020)
  • Table 7. Parkinson's Disease Drugs Injection , by Region USD Million (2015-2020)
  • Table 8. Parkinson's Disease Drugs Transdermal , by Region USD Million (2015-2020)
  • Table 9. Parkinson's Disease Drugs: by End-users(USD Million)
  • Table 10. Parkinson's Disease Drugs Hospitals , by Region USD Million (2015-2020)
  • Table 11. Parkinson's Disease Drugs Clinics , by Region USD Million (2015-2020)
  • Table 12. Parkinson's Disease Drugs Others , by Region USD Million (2015-2020)
  • Table 13. Parkinson's Disease Drugs: by Distribution Channel(USD Million)
  • Table 14. Parkinson's Disease Drugs Hospital , by Region USD Million (2015-2020)
  • Table 15. Parkinson's Disease Drugs Online , by Region USD Million (2015-2020)
  • Table 16. Parkinson's Disease Drugs Retail Pharmacies , by Region USD Million (2015-2020)
  • Table 17. South America Parkinson's Disease Drugs, by Country USD Million (2015-2020)
  • Table 18. South America Parkinson's Disease Drugs, by Type USD Million (2015-2020)
  • Table 19. South America Parkinson's Disease Drugs, by Route of Administration USD Million (2015-2020)
  • Table 20. South America Parkinson's Disease Drugs, by End-users USD Million (2015-2020)
  • Table 21. South America Parkinson's Disease Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 22. Brazil Parkinson's Disease Drugs, by Type USD Million (2015-2020)
  • Table 23. Brazil Parkinson's Disease Drugs, by Route of Administration USD Million (2015-2020)
  • Table 24. Brazil Parkinson's Disease Drugs, by End-users USD Million (2015-2020)
  • Table 25. Brazil Parkinson's Disease Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 26. Argentina Parkinson's Disease Drugs, by Type USD Million (2015-2020)
  • Table 27. Argentina Parkinson's Disease Drugs, by Route of Administration USD Million (2015-2020)
  • Table 28. Argentina Parkinson's Disease Drugs, by End-users USD Million (2015-2020)
  • Table 29. Argentina Parkinson's Disease Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 30. Rest of South America Parkinson's Disease Drugs, by Type USD Million (2015-2020)
  • Table 31. Rest of South America Parkinson's Disease Drugs, by Route of Administration USD Million (2015-2020)
  • Table 32. Rest of South America Parkinson's Disease Drugs, by End-users USD Million (2015-2020)
  • Table 33. Rest of South America Parkinson's Disease Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 34. Asia Pacific Parkinson's Disease Drugs, by Country USD Million (2015-2020)
  • Table 35. Asia Pacific Parkinson's Disease Drugs, by Type USD Million (2015-2020)
  • Table 36. Asia Pacific Parkinson's Disease Drugs, by Route of Administration USD Million (2015-2020)
  • Table 37. Asia Pacific Parkinson's Disease Drugs, by End-users USD Million (2015-2020)
  • Table 38. Asia Pacific Parkinson's Disease Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 39. China Parkinson's Disease Drugs, by Type USD Million (2015-2020)
  • Table 40. China Parkinson's Disease Drugs, by Route of Administration USD Million (2015-2020)
  • Table 41. China Parkinson's Disease Drugs, by End-users USD Million (2015-2020)
  • Table 42. China Parkinson's Disease Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 43. Japan Parkinson's Disease Drugs, by Type USD Million (2015-2020)
  • Table 44. Japan Parkinson's Disease Drugs, by Route of Administration USD Million (2015-2020)
  • Table 45. Japan Parkinson's Disease Drugs, by End-users USD Million (2015-2020)
  • Table 46. Japan Parkinson's Disease Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 47. India Parkinson's Disease Drugs, by Type USD Million (2015-2020)
  • Table 48. India Parkinson's Disease Drugs, by Route of Administration USD Million (2015-2020)
  • Table 49. India Parkinson's Disease Drugs, by End-users USD Million (2015-2020)
  • Table 50. India Parkinson's Disease Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 51. South Korea Parkinson's Disease Drugs, by Type USD Million (2015-2020)
  • Table 52. South Korea Parkinson's Disease Drugs, by Route of Administration USD Million (2015-2020)
  • Table 53. South Korea Parkinson's Disease Drugs, by End-users USD Million (2015-2020)
  • Table 54. South Korea Parkinson's Disease Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 55. Taiwan Parkinson's Disease Drugs, by Type USD Million (2015-2020)
  • Table 56. Taiwan Parkinson's Disease Drugs, by Route of Administration USD Million (2015-2020)
  • Table 57. Taiwan Parkinson's Disease Drugs, by End-users USD Million (2015-2020)
  • Table 58. Taiwan Parkinson's Disease Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 59. Australia Parkinson's Disease Drugs, by Type USD Million (2015-2020)
  • Table 60. Australia Parkinson's Disease Drugs, by Route of Administration USD Million (2015-2020)
  • Table 61. Australia Parkinson's Disease Drugs, by End-users USD Million (2015-2020)
  • Table 62. Australia Parkinson's Disease Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 63. Rest of Asia-Pacific Parkinson's Disease Drugs, by Type USD Million (2015-2020)
  • Table 64. Rest of Asia-Pacific Parkinson's Disease Drugs, by Route of Administration USD Million (2015-2020)
  • Table 65. Rest of Asia-Pacific Parkinson's Disease Drugs, by End-users USD Million (2015-2020)
  • Table 66. Rest of Asia-Pacific Parkinson's Disease Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 67. Europe Parkinson's Disease Drugs, by Country USD Million (2015-2020)
  • Table 68. Europe Parkinson's Disease Drugs, by Type USD Million (2015-2020)
  • Table 69. Europe Parkinson's Disease Drugs, by Route of Administration USD Million (2015-2020)
  • Table 70. Europe Parkinson's Disease Drugs, by End-users USD Million (2015-2020)
  • Table 71. Europe Parkinson's Disease Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 72. Germany Parkinson's Disease Drugs, by Type USD Million (2015-2020)
  • Table 73. Germany Parkinson's Disease Drugs, by Route of Administration USD Million (2015-2020)
  • Table 74. Germany Parkinson's Disease Drugs, by End-users USD Million (2015-2020)
  • Table 75. Germany Parkinson's Disease Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 76. France Parkinson's Disease Drugs, by Type USD Million (2015-2020)
  • Table 77. France Parkinson's Disease Drugs, by Route of Administration USD Million (2015-2020)
  • Table 78. France Parkinson's Disease Drugs, by End-users USD Million (2015-2020)
  • Table 79. France Parkinson's Disease Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 80. Italy Parkinson's Disease Drugs, by Type USD Million (2015-2020)
  • Table 81. Italy Parkinson's Disease Drugs, by Route of Administration USD Million (2015-2020)
  • Table 82. Italy Parkinson's Disease Drugs, by End-users USD Million (2015-2020)
  • Table 83. Italy Parkinson's Disease Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 84. United Kingdom Parkinson's Disease Drugs, by Type USD Million (2015-2020)
  • Table 85. United Kingdom Parkinson's Disease Drugs, by Route of Administration USD Million (2015-2020)
  • Table 86. United Kingdom Parkinson's Disease Drugs, by End-users USD Million (2015-2020)
  • Table 87. United Kingdom Parkinson's Disease Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 88. Netherlands Parkinson's Disease Drugs, by Type USD Million (2015-2020)
  • Table 89. Netherlands Parkinson's Disease Drugs, by Route of Administration USD Million (2015-2020)
  • Table 90. Netherlands Parkinson's Disease Drugs, by End-users USD Million (2015-2020)
  • Table 91. Netherlands Parkinson's Disease Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 92. Rest of Europe Parkinson's Disease Drugs, by Type USD Million (2015-2020)
  • Table 93. Rest of Europe Parkinson's Disease Drugs, by Route of Administration USD Million (2015-2020)
  • Table 94. Rest of Europe Parkinson's Disease Drugs, by End-users USD Million (2015-2020)
  • Table 95. Rest of Europe Parkinson's Disease Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 96. MEA Parkinson's Disease Drugs, by Country USD Million (2015-2020)
  • Table 97. MEA Parkinson's Disease Drugs, by Type USD Million (2015-2020)
  • Table 98. MEA Parkinson's Disease Drugs, by Route of Administration USD Million (2015-2020)
  • Table 99. MEA Parkinson's Disease Drugs, by End-users USD Million (2015-2020)
  • Table 100. MEA Parkinson's Disease Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 101. Middle East Parkinson's Disease Drugs, by Type USD Million (2015-2020)
  • Table 102. Middle East Parkinson's Disease Drugs, by Route of Administration USD Million (2015-2020)
  • Table 103. Middle East Parkinson's Disease Drugs, by End-users USD Million (2015-2020)
  • Table 104. Middle East Parkinson's Disease Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 105. Africa Parkinson's Disease Drugs, by Type USD Million (2015-2020)
  • Table 106. Africa Parkinson's Disease Drugs, by Route of Administration USD Million (2015-2020)
  • Table 107. Africa Parkinson's Disease Drugs, by End-users USD Million (2015-2020)
  • Table 108. Africa Parkinson's Disease Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 109. North America Parkinson's Disease Drugs, by Country USD Million (2015-2020)
  • Table 110. North America Parkinson's Disease Drugs, by Type USD Million (2015-2020)
  • Table 111. North America Parkinson's Disease Drugs, by Route of Administration USD Million (2015-2020)
  • Table 112. North America Parkinson's Disease Drugs, by End-users USD Million (2015-2020)
  • Table 113. North America Parkinson's Disease Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 114. United States Parkinson's Disease Drugs, by Type USD Million (2015-2020)
  • Table 115. United States Parkinson's Disease Drugs, by Route of Administration USD Million (2015-2020)
  • Table 116. United States Parkinson's Disease Drugs, by End-users USD Million (2015-2020)
  • Table 117. United States Parkinson's Disease Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 118. Canada Parkinson's Disease Drugs, by Type USD Million (2015-2020)
  • Table 119. Canada Parkinson's Disease Drugs, by Route of Administration USD Million (2015-2020)
  • Table 120. Canada Parkinson's Disease Drugs, by End-users USD Million (2015-2020)
  • Table 121. Canada Parkinson's Disease Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 122. Mexico Parkinson's Disease Drugs, by Type USD Million (2015-2020)
  • Table 123. Mexico Parkinson's Disease Drugs, by Route of Administration USD Million (2015-2020)
  • Table 124. Mexico Parkinson's Disease Drugs, by End-users USD Million (2015-2020)
  • Table 125. Mexico Parkinson's Disease Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 126. Parkinson's Disease Drugs Sales: by Type(K Units)
  • Table 127. Parkinson's Disease Drugs Sales Carbidopa/Levodopa , by Region K Units (2015-2020)
  • Table 128. Parkinson's Disease Drugs Sales Dopamine Receptor Agonists , by Region K Units (2015-2020)
  • Table 129. Parkinson's Disease Drugs Sales MAO-Inhibitors , by Region K Units (2015-2020)
  • Table 130. Parkinson's Disease Drugs Sales: by Route of Administration(K Units)
  • Table 131. Parkinson's Disease Drugs Sales Oral , by Region K Units (2015-2020)
  • Table 132. Parkinson's Disease Drugs Sales Injection , by Region K Units (2015-2020)
  • Table 133. Parkinson's Disease Drugs Sales Transdermal , by Region K Units (2015-2020)
  • Table 134. Parkinson's Disease Drugs Sales: by End-users(K Units)
  • Table 135. Parkinson's Disease Drugs Sales Hospitals , by Region K Units (2015-2020)
  • Table 136. Parkinson's Disease Drugs Sales Clinics , by Region K Units (2015-2020)
  • Table 137. Parkinson's Disease Drugs Sales Others , by Region K Units (2015-2020)
  • Table 138. Parkinson's Disease Drugs Sales: by Distribution Channel(K Units)
  • Table 139. Parkinson's Disease Drugs Sales Hospital , by Region K Units (2015-2020)
  • Table 140. Parkinson's Disease Drugs Sales Online , by Region K Units (2015-2020)
  • Table 141. Parkinson's Disease Drugs Sales Retail Pharmacies , by Region K Units (2015-2020)
  • Table 142. South America Parkinson's Disease Drugs Sales, by Country K Units (2015-2020)
  • Table 143. South America Parkinson's Disease Drugs Sales, by Type K Units (2015-2020)
  • Table 144. South America Parkinson's Disease Drugs Sales, by Route of Administration K Units (2015-2020)
  • Table 145. South America Parkinson's Disease Drugs Sales, by End-users K Units (2015-2020)
  • Table 146. South America Parkinson's Disease Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 147. Brazil Parkinson's Disease Drugs Sales, by Type K Units (2015-2020)
  • Table 148. Brazil Parkinson's Disease Drugs Sales, by Route of Administration K Units (2015-2020)
  • Table 149. Brazil Parkinson's Disease Drugs Sales, by End-users K Units (2015-2020)
  • Table 150. Brazil Parkinson's Disease Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 151. Argentina Parkinson's Disease Drugs Sales, by Type K Units (2015-2020)
  • Table 152. Argentina Parkinson's Disease Drugs Sales, by Route of Administration K Units (2015-2020)
  • Table 153. Argentina Parkinson's Disease Drugs Sales, by End-users K Units (2015-2020)
  • Table 154. Argentina Parkinson's Disease Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 155. Rest of South America Parkinson's Disease Drugs Sales, by Type K Units (2015-2020)
  • Table 156. Rest of South America Parkinson's Disease Drugs Sales, by Route of Administration K Units (2015-2020)
  • Table 157. Rest of South America Parkinson's Disease Drugs Sales, by End-users K Units (2015-2020)
  • Table 158. Rest of South America Parkinson's Disease Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 159. Asia Pacific Parkinson's Disease Drugs Sales, by Country K Units (2015-2020)
  • Table 160. Asia Pacific Parkinson's Disease Drugs Sales, by Type K Units (2015-2020)
  • Table 161. Asia Pacific Parkinson's Disease Drugs Sales, by Route of Administration K Units (2015-2020)
  • Table 162. Asia Pacific Parkinson's Disease Drugs Sales, by End-users K Units (2015-2020)
  • Table 163. Asia Pacific Parkinson's Disease Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 164. China Parkinson's Disease Drugs Sales, by Type K Units (2015-2020)
  • Table 165. China Parkinson's Disease Drugs Sales, by Route of Administration K Units (2015-2020)
  • Table 166. China Parkinson's Disease Drugs Sales, by End-users K Units (2015-2020)
  • Table 167. China Parkinson's Disease Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 168. Japan Parkinson's Disease Drugs Sales, by Type K Units (2015-2020)
  • Table 169. Japan Parkinson's Disease Drugs Sales, by Route of Administration K Units (2015-2020)
  • Table 170. Japan Parkinson's Disease Drugs Sales, by End-users K Units (2015-2020)
  • Table 171. Japan Parkinson's Disease Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 172. India Parkinson's Disease Drugs Sales, by Type K Units (2015-2020)
  • Table 173. India Parkinson's Disease Drugs Sales, by Route of Administration K Units (2015-2020)
  • Table 174. India Parkinson's Disease Drugs Sales, by End-users K Units (2015-2020)
  • Table 175. India Parkinson's Disease Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 176. South Korea Parkinson's Disease Drugs Sales, by Type K Units (2015-2020)
  • Table 177. South Korea Parkinson's Disease Drugs Sales, by Route of Administration K Units (2015-2020)
  • Table 178. South Korea Parkinson's Disease Drugs Sales, by End-users K Units (2015-2020)
  • Table 179. South Korea Parkinson's Disease Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 180. Taiwan Parkinson's Disease Drugs Sales, by Type K Units (2015-2020)
  • Table 181. Taiwan Parkinson's Disease Drugs Sales, by Route of Administration K Units (2015-2020)
  • Table 182. Taiwan Parkinson's Disease Drugs Sales, by End-users K Units (2015-2020)
  • Table 183. Taiwan Parkinson's Disease Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 184. Australia Parkinson's Disease Drugs Sales, by Type K Units (2015-2020)
  • Table 185. Australia Parkinson's Disease Drugs Sales, by Route of Administration K Units (2015-2020)
  • Table 186. Australia Parkinson's Disease Drugs Sales, by End-users K Units (2015-2020)
  • Table 187. Australia Parkinson's Disease Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 188. Rest of Asia-Pacific Parkinson's Disease Drugs Sales, by Type K Units (2015-2020)
  • Table 189. Rest of Asia-Pacific Parkinson's Disease Drugs Sales, by Route of Administration K Units (2015-2020)
  • Table 190. Rest of Asia-Pacific Parkinson's Disease Drugs Sales, by End-users K Units (2015-2020)
  • Table 191. Rest of Asia-Pacific Parkinson's Disease Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 192. Europe Parkinson's Disease Drugs Sales, by Country K Units (2015-2020)
  • Table 193. Europe Parkinson's Disease Drugs Sales, by Type K Units (2015-2020)
  • Table 194. Europe Parkinson's Disease Drugs Sales, by Route of Administration K Units (2015-2020)
  • Table 195. Europe Parkinson's Disease Drugs Sales, by End-users K Units (2015-2020)
  • Table 196. Europe Parkinson's Disease Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 197. Germany Parkinson's Disease Drugs Sales, by Type K Units (2015-2020)
  • Table 198. Germany Parkinson's Disease Drugs Sales, by Route of Administration K Units (2015-2020)
  • Table 199. Germany Parkinson's Disease Drugs Sales, by End-users K Units (2015-2020)
  • Table 200. Germany Parkinson's Disease Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 201. France Parkinson's Disease Drugs Sales, by Type K Units (2015-2020)
  • Table 202. France Parkinson's Disease Drugs Sales, by Route of Administration K Units (2015-2020)
  • Table 203. France Parkinson's Disease Drugs Sales, by End-users K Units (2015-2020)
  • Table 204. France Parkinson's Disease Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 205. Italy Parkinson's Disease Drugs Sales, by Type K Units (2015-2020)
  • Table 206. Italy Parkinson's Disease Drugs Sales, by Route of Administration K Units (2015-2020)
  • Table 207. Italy Parkinson's Disease Drugs Sales, by End-users K Units (2015-2020)
  • Table 208. Italy Parkinson's Disease Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 209. United Kingdom Parkinson's Disease Drugs Sales, by Type K Units (2015-2020)
  • Table 210. United Kingdom Parkinson's Disease Drugs Sales, by Route of Administration K Units (2015-2020)
  • Table 211. United Kingdom Parkinson's Disease Drugs Sales, by End-users K Units (2015-2020)
  • Table 212. United Kingdom Parkinson's Disease Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 213. Netherlands Parkinson's Disease Drugs Sales, by Type K Units (2015-2020)
  • Table 214. Netherlands Parkinson's Disease Drugs Sales, by Route of Administration K Units (2015-2020)
  • Table 215. Netherlands Parkinson's Disease Drugs Sales, by End-users K Units (2015-2020)
  • Table 216. Netherlands Parkinson's Disease Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 217. Rest of Europe Parkinson's Disease Drugs Sales, by Type K Units (2015-2020)
  • Table 218. Rest of Europe Parkinson's Disease Drugs Sales, by Route of Administration K Units (2015-2020)
  • Table 219. Rest of Europe Parkinson's Disease Drugs Sales, by End-users K Units (2015-2020)
  • Table 220. Rest of Europe Parkinson's Disease Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 221. MEA Parkinson's Disease Drugs Sales, by Country K Units (2015-2020)
  • Table 222. MEA Parkinson's Disease Drugs Sales, by Type K Units (2015-2020)
  • Table 223. MEA Parkinson's Disease Drugs Sales, by Route of Administration K Units (2015-2020)
  • Table 224. MEA Parkinson's Disease Drugs Sales, by End-users K Units (2015-2020)
  • Table 225. MEA Parkinson's Disease Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 226. Middle East Parkinson's Disease Drugs Sales, by Type K Units (2015-2020)
  • Table 227. Middle East Parkinson's Disease Drugs Sales, by Route of Administration K Units (2015-2020)
  • Table 228. Middle East Parkinson's Disease Drugs Sales, by End-users K Units (2015-2020)
  • Table 229. Middle East Parkinson's Disease Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 230. Africa Parkinson's Disease Drugs Sales, by Type K Units (2015-2020)
  • Table 231. Africa Parkinson's Disease Drugs Sales, by Route of Administration K Units (2015-2020)
  • Table 232. Africa Parkinson's Disease Drugs Sales, by End-users K Units (2015-2020)
  • Table 233. Africa Parkinson's Disease Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 234. North America Parkinson's Disease Drugs Sales, by Country K Units (2015-2020)
  • Table 235. North America Parkinson's Disease Drugs Sales, by Type K Units (2015-2020)
  • Table 236. North America Parkinson's Disease Drugs Sales, by Route of Administration K Units (2015-2020)
  • Table 237. North America Parkinson's Disease Drugs Sales, by End-users K Units (2015-2020)
  • Table 238. North America Parkinson's Disease Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 239. United States Parkinson's Disease Drugs Sales, by Type K Units (2015-2020)
  • Table 240. United States Parkinson's Disease Drugs Sales, by Route of Administration K Units (2015-2020)
  • Table 241. United States Parkinson's Disease Drugs Sales, by End-users K Units (2015-2020)
  • Table 242. United States Parkinson's Disease Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 243. Canada Parkinson's Disease Drugs Sales, by Type K Units (2015-2020)
  • Table 244. Canada Parkinson's Disease Drugs Sales, by Route of Administration K Units (2015-2020)
  • Table 245. Canada Parkinson's Disease Drugs Sales, by End-users K Units (2015-2020)
  • Table 246. Canada Parkinson's Disease Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 247. Mexico Parkinson's Disease Drugs Sales, by Type K Units (2015-2020)
  • Table 248. Mexico Parkinson's Disease Drugs Sales, by Route of Administration K Units (2015-2020)
  • Table 249. Mexico Parkinson's Disease Drugs Sales, by End-users K Units (2015-2020)
  • Table 250. Mexico Parkinson's Disease Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 251. Parkinson's Disease Drugs: by Type(USD/Units)
  • Table 252. Company Basic Information, Sales Area and Its Competitors
  • Table 253. Company Basic Information, Sales Area and Its Competitors
  • Table 254. Company Basic Information, Sales Area and Its Competitors
  • Table 255. Company Basic Information, Sales Area and Its Competitors
  • Table 256. Company Basic Information, Sales Area and Its Competitors
  • Table 257. Company Basic Information, Sales Area and Its Competitors
  • Table 258. Company Basic Information, Sales Area and Its Competitors
  • Table 259. Company Basic Information, Sales Area and Its Competitors
  • Table 260. Company Basic Information, Sales Area and Its Competitors
  • Table 261. Company Basic Information, Sales Area and Its Competitors
  • Table 262. Company Basic Information, Sales Area and Its Competitors
  • Table 263. Company Basic Information, Sales Area and Its Competitors
  • Table 264. Company Basic Information, Sales Area and Its Competitors
  • Table 265. Company Basic Information, Sales Area and Its Competitors
  • Table 266. Company Basic Information, Sales Area and Its Competitors
  • Table 267. Company Basic Information, Sales Area and Its Competitors
  • Table 268. Company Basic Information, Sales Area and Its Competitors
  • Table 269. Company Basic Information, Sales Area and Its Competitors
  • Table 270. Parkinson's Disease Drugs: by Type(USD Million)
  • Table 271. Parkinson's Disease Drugs Carbidopa/Levodopa , by Region USD Million (2021-2026)
  • Table 272. Parkinson's Disease Drugs Dopamine Receptor Agonists , by Region USD Million (2021-2026)
  • Table 273. Parkinson's Disease Drugs MAO-Inhibitors , by Region USD Million (2021-2026)
  • Table 274. Parkinson's Disease Drugs: by Route of Administration(USD Million)
  • Table 275. Parkinson's Disease Drugs Oral , by Region USD Million (2021-2026)
  • Table 276. Parkinson's Disease Drugs Injection , by Region USD Million (2021-2026)
  • Table 277. Parkinson's Disease Drugs Transdermal , by Region USD Million (2021-2026)
  • Table 278. Parkinson's Disease Drugs: by End-users(USD Million)
  • Table 279. Parkinson's Disease Drugs Hospitals , by Region USD Million (2021-2026)
  • Table 280. Parkinson's Disease Drugs Clinics , by Region USD Million (2021-2026)
  • Table 281. Parkinson's Disease Drugs Others , by Region USD Million (2021-2026)
  • Table 282. Parkinson's Disease Drugs: by Distribution Channel(USD Million)
  • Table 283. Parkinson's Disease Drugs Hospital , by Region USD Million (2021-2026)
  • Table 284. Parkinson's Disease Drugs Online , by Region USD Million (2021-2026)
  • Table 285. Parkinson's Disease Drugs Retail Pharmacies , by Region USD Million (2021-2026)
  • Table 286. South America Parkinson's Disease Drugs, by Country USD Million (2021-2026)
  • Table 287. South America Parkinson's Disease Drugs, by Type USD Million (2021-2026)
  • Table 288. South America Parkinson's Disease Drugs, by Route of Administration USD Million (2021-2026)
  • Table 289. South America Parkinson's Disease Drugs, by End-users USD Million (2021-2026)
  • Table 290. South America Parkinson's Disease Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 291. Brazil Parkinson's Disease Drugs, by Type USD Million (2021-2026)
  • Table 292. Brazil Parkinson's Disease Drugs, by Route of Administration USD Million (2021-2026)
  • Table 293. Brazil Parkinson's Disease Drugs, by End-users USD Million (2021-2026)
  • Table 294. Brazil Parkinson's Disease Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 295. Argentina Parkinson's Disease Drugs, by Type USD Million (2021-2026)
  • Table 296. Argentina Parkinson's Disease Drugs, by Route of Administration USD Million (2021-2026)
  • Table 297. Argentina Parkinson's Disease Drugs, by End-users USD Million (2021-2026)
  • Table 298. Argentina Parkinson's Disease Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 299. Rest of South America Parkinson's Disease Drugs, by Type USD Million (2021-2026)
  • Table 300. Rest of South America Parkinson's Disease Drugs, by Route of Administration USD Million (2021-2026)
  • Table 301. Rest of South America Parkinson's Disease Drugs, by End-users USD Million (2021-2026)
  • Table 302. Rest of South America Parkinson's Disease Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 303. Asia Pacific Parkinson's Disease Drugs, by Country USD Million (2021-2026)
  • Table 304. Asia Pacific Parkinson's Disease Drugs, by Type USD Million (2021-2026)
  • Table 305. Asia Pacific Parkinson's Disease Drugs, by Route of Administration USD Million (2021-2026)
  • Table 306. Asia Pacific Parkinson's Disease Drugs, by End-users USD Million (2021-2026)
  • Table 307. Asia Pacific Parkinson's Disease Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 308. China Parkinson's Disease Drugs, by Type USD Million (2021-2026)
  • Table 309. China Parkinson's Disease Drugs, by Route of Administration USD Million (2021-2026)
  • Table 310. China Parkinson's Disease Drugs, by End-users USD Million (2021-2026)
  • Table 311. China Parkinson's Disease Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 312. Japan Parkinson's Disease Drugs, by Type USD Million (2021-2026)
  • Table 313. Japan Parkinson's Disease Drugs, by Route of Administration USD Million (2021-2026)
  • Table 314. Japan Parkinson's Disease Drugs, by End-users USD Million (2021-2026)
  • Table 315. Japan Parkinson's Disease Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 316. India Parkinson's Disease Drugs, by Type USD Million (2021-2026)
  • Table 317. India Parkinson's Disease Drugs, by Route of Administration USD Million (2021-2026)
  • Table 318. India Parkinson's Disease Drugs, by End-users USD Million (2021-2026)
  • Table 319. India Parkinson's Disease Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 320. South Korea Parkinson's Disease Drugs, by Type USD Million (2021-2026)
  • Table 321. South Korea Parkinson's Disease Drugs, by Route of Administration USD Million (2021-2026)
  • Table 322. South Korea Parkinson's Disease Drugs, by End-users USD Million (2021-2026)
  • Table 323. South Korea Parkinson's Disease Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 324. Taiwan Parkinson's Disease Drugs, by Type USD Million (2021-2026)
  • Table 325. Taiwan Parkinson's Disease Drugs, by Route of Administration USD Million (2021-2026)
  • Table 326. Taiwan Parkinson's Disease Drugs, by End-users USD Million (2021-2026)
  • Table 327. Taiwan Parkinson's Disease Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 328. Australia Parkinson's Disease Drugs, by Type USD Million (2021-2026)
  • Table 329. Australia Parkinson's Disease Drugs, by Route of Administration USD Million (2021-2026)
  • Table 330. Australia Parkinson's Disease Drugs, by End-users USD Million (2021-2026)
  • Table 331. Australia Parkinson's Disease Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 332. Rest of Asia-Pacific Parkinson's Disease Drugs, by Type USD Million (2021-2026)
  • Table 333. Rest of Asia-Pacific Parkinson's Disease Drugs, by Route of Administration USD Million (2021-2026)
  • Table 334. Rest of Asia-Pacific Parkinson's Disease Drugs, by End-users USD Million (2021-2026)
  • Table 335. Rest of Asia-Pacific Parkinson's Disease Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 336. Europe Parkinson's Disease Drugs, by Country USD Million (2021-2026)
  • Table 337. Europe Parkinson's Disease Drugs, by Type USD Million (2021-2026)
  • Table 338. Europe Parkinson's Disease Drugs, by Route of Administration USD Million (2021-2026)
  • Table 339. Europe Parkinson's Disease Drugs, by End-users USD Million (2021-2026)
  • Table 340. Europe Parkinson's Disease Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 341. Germany Parkinson's Disease Drugs, by Type USD Million (2021-2026)
  • Table 342. Germany Parkinson's Disease Drugs, by Route of Administration USD Million (2021-2026)
  • Table 343. Germany Parkinson's Disease Drugs, by End-users USD Million (2021-2026)
  • Table 344. Germany Parkinson's Disease Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 345. France Parkinson's Disease Drugs, by Type USD Million (2021-2026)
  • Table 346. France Parkinson's Disease Drugs, by Route of Administration USD Million (2021-2026)
  • Table 347. France Parkinson's Disease Drugs, by End-users USD Million (2021-2026)
  • Table 348. France Parkinson's Disease Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 349. Italy Parkinson's Disease Drugs, by Type USD Million (2021-2026)
  • Table 350. Italy Parkinson's Disease Drugs, by Route of Administration USD Million (2021-2026)
  • Table 351. Italy Parkinson's Disease Drugs, by End-users USD Million (2021-2026)
  • Table 352. Italy Parkinson's Disease Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 353. United Kingdom Parkinson's Disease Drugs, by Type USD Million (2021-2026)
  • Table 354. United Kingdom Parkinson's Disease Drugs, by Route of Administration USD Million (2021-2026)
  • Table 355. United Kingdom Parkinson's Disease Drugs, by End-users USD Million (2021-2026)
  • Table 356. United Kingdom Parkinson's Disease Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 357. Netherlands Parkinson's Disease Drugs, by Type USD Million (2021-2026)
  • Table 358. Netherlands Parkinson's Disease Drugs, by Route of Administration USD Million (2021-2026)
  • Table 359. Netherlands Parkinson's Disease Drugs, by End-users USD Million (2021-2026)
  • Table 360. Netherlands Parkinson's Disease Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 361. Rest of Europe Parkinson's Disease Drugs, by Type USD Million (2021-2026)
  • Table 362. Rest of Europe Parkinson's Disease Drugs, by Route of Administration USD Million (2021-2026)
  • Table 363. Rest of Europe Parkinson's Disease Drugs, by End-users USD Million (2021-2026)
  • Table 364. Rest of Europe Parkinson's Disease Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 365. MEA Parkinson's Disease Drugs, by Country USD Million (2021-2026)
  • Table 366. MEA Parkinson's Disease Drugs, by Type USD Million (2021-2026)
  • Table 367. MEA Parkinson's Disease Drugs, by Route of Administration USD Million (2021-2026)
  • Table 368. MEA Parkinson's Disease Drugs, by End-users USD Million (2021-2026)
  • Table 369. MEA Parkinson's Disease Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 370. Middle East Parkinson's Disease Drugs, by Type USD Million (2021-2026)
  • Table 371. Middle East Parkinson's Disease Drugs, by Route of Administration USD Million (2021-2026)
  • Table 372. Middle East Parkinson's Disease Drugs, by End-users USD Million (2021-2026)
  • Table 373. Middle East Parkinson's Disease Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 374. Africa Parkinson's Disease Drugs, by Type USD Million (2021-2026)
  • Table 375. Africa Parkinson's Disease Drugs, by Route of Administration USD Million (2021-2026)
  • Table 376. Africa Parkinson's Disease Drugs, by End-users USD Million (2021-2026)
  • Table 377. Africa Parkinson's Disease Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 378. North America Parkinson's Disease Drugs, by Country USD Million (2021-2026)
  • Table 379. North America Parkinson's Disease Drugs, by Type USD Million (2021-2026)
  • Table 380. North America Parkinson's Disease Drugs, by Route of Administration USD Million (2021-2026)
  • Table 381. North America Parkinson's Disease Drugs, by End-users USD Million (2021-2026)
  • Table 382. North America Parkinson's Disease Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 383. United States Parkinson's Disease Drugs, by Type USD Million (2021-2026)
  • Table 384. United States Parkinson's Disease Drugs, by Route of Administration USD Million (2021-2026)
  • Table 385. United States Parkinson's Disease Drugs, by End-users USD Million (2021-2026)
  • Table 386. United States Parkinson's Disease Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 387. Canada Parkinson's Disease Drugs, by Type USD Million (2021-2026)
  • Table 388. Canada Parkinson's Disease Drugs, by Route of Administration USD Million (2021-2026)
  • Table 389. Canada Parkinson's Disease Drugs, by End-users USD Million (2021-2026)
  • Table 390. Canada Parkinson's Disease Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 391. Mexico Parkinson's Disease Drugs, by Type USD Million (2021-2026)
  • Table 392. Mexico Parkinson's Disease Drugs, by Route of Administration USD Million (2021-2026)
  • Table 393. Mexico Parkinson's Disease Drugs, by End-users USD Million (2021-2026)
  • Table 394. Mexico Parkinson's Disease Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 395. Parkinson's Disease Drugs Sales: by Type(K Units)
  • Table 396. Parkinson's Disease Drugs Sales Carbidopa/Levodopa , by Region K Units (2021-2026)
  • Table 397. Parkinson's Disease Drugs Sales Dopamine Receptor Agonists , by Region K Units (2021-2026)
  • Table 398. Parkinson's Disease Drugs Sales MAO-Inhibitors , by Region K Units (2021-2026)
  • Table 399. Parkinson's Disease Drugs Sales: by Route of Administration(K Units)
  • Table 400. Parkinson's Disease Drugs Sales Oral , by Region K Units (2021-2026)
  • Table 401. Parkinson's Disease Drugs Sales Injection , by Region K Units (2021-2026)
  • Table 402. Parkinson's Disease Drugs Sales Transdermal , by Region K Units (2021-2026)
  • Table 403. Parkinson's Disease Drugs Sales: by End-users(K Units)
  • Table 404. Parkinson's Disease Drugs Sales Hospitals , by Region K Units (2021-2026)
  • Table 405. Parkinson's Disease Drugs Sales Clinics , by Region K Units (2021-2026)
  • Table 406. Parkinson's Disease Drugs Sales Others , by Region K Units (2021-2026)
  • Table 407. Parkinson's Disease Drugs Sales: by Distribution Channel(K Units)
  • Table 408. Parkinson's Disease Drugs Sales Hospital , by Region K Units (2021-2026)
  • Table 409. Parkinson's Disease Drugs Sales Online , by Region K Units (2021-2026)
  • Table 410. Parkinson's Disease Drugs Sales Retail Pharmacies , by Region K Units (2021-2026)
  • Table 411. South America Parkinson's Disease Drugs Sales, by Country K Units (2021-2026)
  • Table 412. South America Parkinson's Disease Drugs Sales, by Type K Units (2021-2026)
  • Table 413. South America Parkinson's Disease Drugs Sales, by Route of Administration K Units (2021-2026)
  • Table 414. South America Parkinson's Disease Drugs Sales, by End-users K Units (2021-2026)
  • Table 415. South America Parkinson's Disease Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 416. Brazil Parkinson's Disease Drugs Sales, by Type K Units (2021-2026)
  • Table 417. Brazil Parkinson's Disease Drugs Sales, by Route of Administration K Units (2021-2026)
  • Table 418. Brazil Parkinson's Disease Drugs Sales, by End-users K Units (2021-2026)
  • Table 419. Brazil Parkinson's Disease Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 420. Argentina Parkinson's Disease Drugs Sales, by Type K Units (2021-2026)
  • Table 421. Argentina Parkinson's Disease Drugs Sales, by Route of Administration K Units (2021-2026)
  • Table 422. Argentina Parkinson's Disease Drugs Sales, by End-users K Units (2021-2026)
  • Table 423. Argentina Parkinson's Disease Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 424. Rest of South America Parkinson's Disease Drugs Sales, by Type K Units (2021-2026)
  • Table 425. Rest of South America Parkinson's Disease Drugs Sales, by Route of Administration K Units (2021-2026)
  • Table 426. Rest of South America Parkinson's Disease Drugs Sales, by End-users K Units (2021-2026)
  • Table 427. Rest of South America Parkinson's Disease Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 428. Asia Pacific Parkinson's Disease Drugs Sales, by Country K Units (2021-2026)
  • Table 429. Asia Pacific Parkinson's Disease Drugs Sales, by Type K Units (2021-2026)
  • Table 430. Asia Pacific Parkinson's Disease Drugs Sales, by Route of Administration K Units (2021-2026)
  • Table 431. Asia Pacific Parkinson's Disease Drugs Sales, by End-users K Units (2021-2026)
  • Table 432. Asia Pacific Parkinson's Disease Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 433. China Parkinson's Disease Drugs Sales, by Type K Units (2021-2026)
  • Table 434. China Parkinson's Disease Drugs Sales, by Route of Administration K Units (2021-2026)
  • Table 435. China Parkinson's Disease Drugs Sales, by End-users K Units (2021-2026)
  • Table 436. China Parkinson's Disease Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 437. Japan Parkinson's Disease Drugs Sales, by Type K Units (2021-2026)
  • Table 438. Japan Parkinson's Disease Drugs Sales, by Route of Administration K Units (2021-2026)
  • Table 439. Japan Parkinson's Disease Drugs Sales, by End-users K Units (2021-2026)
  • Table 440. Japan Parkinson's Disease Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 441. India Parkinson's Disease Drugs Sales, by Type K Units (2021-2026)
  • Table 442. India Parkinson's Disease Drugs Sales, by Route of Administration K Units (2021-2026)
  • Table 443. India Parkinson's Disease Drugs Sales, by End-users K Units (2021-2026)
  • Table 444. India Parkinson's Disease Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 445. South Korea Parkinson's Disease Drugs Sales, by Type K Units (2021-2026)
  • Table 446. South Korea Parkinson's Disease Drugs Sales, by Route of Administration K Units (2021-2026)
  • Table 447. South Korea Parkinson's Disease Drugs Sales, by End-users K Units (2021-2026)
  • Table 448. South Korea Parkinson's Disease Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 449. Taiwan Parkinson's Disease Drugs Sales, by Type K Units (2021-2026)
  • Table 450. Taiwan Parkinson's Disease Drugs Sales, by Route of Administration K Units (2021-2026)
  • Table 451. Taiwan Parkinson's Disease Drugs Sales, by End-users K Units (2021-2026)
  • Table 452. Taiwan Parkinson's Disease Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 453. Australia Parkinson's Disease Drugs Sales, by Type K Units (2021-2026)
  • Table 454. Australia Parkinson's Disease Drugs Sales, by Route of Administration K Units (2021-2026)
  • Table 455. Australia Parkinson's Disease Drugs Sales, by End-users K Units (2021-2026)
  • Table 456. Australia Parkinson's Disease Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 457. Rest of Asia-Pacific Parkinson's Disease Drugs Sales, by Type K Units (2021-2026)
  • Table 458. Rest of Asia-Pacific Parkinson's Disease Drugs Sales, by Route of Administration K Units (2021-2026)
  • Table 459. Rest of Asia-Pacific Parkinson's Disease Drugs Sales, by End-users K Units (2021-2026)
  • Table 460. Rest of Asia-Pacific Parkinson's Disease Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 461. Europe Parkinson's Disease Drugs Sales, by Country K Units (2021-2026)
  • Table 462. Europe Parkinson's Disease Drugs Sales, by Type K Units (2021-2026)
  • Table 463. Europe Parkinson's Disease Drugs Sales, by Route of Administration K Units (2021-2026)
  • Table 464. Europe Parkinson's Disease Drugs Sales, by End-users K Units (2021-2026)
  • Table 465. Europe Parkinson's Disease Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 466. Germany Parkinson's Disease Drugs Sales, by Type K Units (2021-2026)
  • Table 467. Germany Parkinson's Disease Drugs Sales, by Route of Administration K Units (2021-2026)
  • Table 468. Germany Parkinson's Disease Drugs Sales, by End-users K Units (2021-2026)
  • Table 469. Germany Parkinson's Disease Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 470. France Parkinson's Disease Drugs Sales, by Type K Units (2021-2026)
  • Table 471. France Parkinson's Disease Drugs Sales, by Route of Administration K Units (2021-2026)
  • Table 472. France Parkinson's Disease Drugs Sales, by End-users K Units (2021-2026)
  • Table 473. France Parkinson's Disease Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 474. Italy Parkinson's Disease Drugs Sales, by Type K Units (2021-2026)
  • Table 475. Italy Parkinson's Disease Drugs Sales, by Route of Administration K Units (2021-2026)
  • Table 476. Italy Parkinson's Disease Drugs Sales, by End-users K Units (2021-2026)
  • Table 477. Italy Parkinson's Disease Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 478. United Kingdom Parkinson's Disease Drugs Sales, by Type K Units (2021-2026)
  • Table 479. United Kingdom Parkinson's Disease Drugs Sales, by Route of Administration K Units (2021-2026)
  • Table 480. United Kingdom Parkinson's Disease Drugs Sales, by End-users K Units (2021-2026)
  • Table 481. United Kingdom Parkinson's Disease Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 482. Netherlands Parkinson's Disease Drugs Sales, by Type K Units (2021-2026)
  • Table 483. Netherlands Parkinson's Disease Drugs Sales, by Route of Administration K Units (2021-2026)
  • Table 484. Netherlands Parkinson's Disease Drugs Sales, by End-users K Units (2021-2026)
  • Table 485. Netherlands Parkinson's Disease Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 486. Rest of Europe Parkinson's Disease Drugs Sales, by Type K Units (2021-2026)
  • Table 487. Rest of Europe Parkinson's Disease Drugs Sales, by Route of Administration K Units (2021-2026)
  • Table 488. Rest of Europe Parkinson's Disease Drugs Sales, by End-users K Units (2021-2026)
  • Table 489. Rest of Europe Parkinson's Disease Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 490. MEA Parkinson's Disease Drugs Sales, by Country K Units (2021-2026)
  • Table 491. MEA Parkinson's Disease Drugs Sales, by Type K Units (2021-2026)
  • Table 492. MEA Parkinson's Disease Drugs Sales, by Route of Administration K Units (2021-2026)
  • Table 493. MEA Parkinson's Disease Drugs Sales, by End-users K Units (2021-2026)
  • Table 494. MEA Parkinson's Disease Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 495. Middle East Parkinson's Disease Drugs Sales, by Type K Units (2021-2026)
  • Table 496. Middle East Parkinson's Disease Drugs Sales, by Route of Administration K Units (2021-2026)
  • Table 497. Middle East Parkinson's Disease Drugs Sales, by End-users K Units (2021-2026)
  • Table 498. Middle East Parkinson's Disease Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 499. Africa Parkinson's Disease Drugs Sales, by Type K Units (2021-2026)
  • Table 500. Africa Parkinson's Disease Drugs Sales, by Route of Administration K Units (2021-2026)
  • Table 501. Africa Parkinson's Disease Drugs Sales, by End-users K Units (2021-2026)
  • Table 502. Africa Parkinson's Disease Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 503. North America Parkinson's Disease Drugs Sales, by Country K Units (2021-2026)
  • Table 504. North America Parkinson's Disease Drugs Sales, by Type K Units (2021-2026)
  • Table 505. North America Parkinson's Disease Drugs Sales, by Route of Administration K Units (2021-2026)
  • Table 506. North America Parkinson's Disease Drugs Sales, by End-users K Units (2021-2026)
  • Table 507. North America Parkinson's Disease Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 508. United States Parkinson's Disease Drugs Sales, by Type K Units (2021-2026)
  • Table 509. United States Parkinson's Disease Drugs Sales, by Route of Administration K Units (2021-2026)
  • Table 510. United States Parkinson's Disease Drugs Sales, by End-users K Units (2021-2026)
  • Table 511. United States Parkinson's Disease Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 512. Canada Parkinson's Disease Drugs Sales, by Type K Units (2021-2026)
  • Table 513. Canada Parkinson's Disease Drugs Sales, by Route of Administration K Units (2021-2026)
  • Table 514. Canada Parkinson's Disease Drugs Sales, by End-users K Units (2021-2026)
  • Table 515. Canada Parkinson's Disease Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 516. Mexico Parkinson's Disease Drugs Sales, by Type K Units (2021-2026)
  • Table 517. Mexico Parkinson's Disease Drugs Sales, by Route of Administration K Units (2021-2026)
  • Table 518. Mexico Parkinson's Disease Drugs Sales, by End-users K Units (2021-2026)
  • Table 519. Mexico Parkinson's Disease Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 520. Parkinson's Disease Drugs: by Type(USD/Units)
  • Table 521. Research Programs/Design for This Report
  • Table 522. Key Data Information from Secondary Sources
  • Table 523. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Parkinson's Disease Drugs: by Type USD Million (2015-2020)
  • Figure 5. Global Parkinson's Disease Drugs: by Route of Administration USD Million (2015-2020)
  • Figure 6. Global Parkinson's Disease Drugs: by End-users USD Million (2015-2020)
  • Figure 7. Global Parkinson's Disease Drugs: by Distribution Channel USD Million (2015-2020)
  • Figure 8. South America Parkinson's Disease Drugs Share (%), by Country
  • Figure 9. Asia Pacific Parkinson's Disease Drugs Share (%), by Country
  • Figure 10. Europe Parkinson's Disease Drugs Share (%), by Country
  • Figure 11. MEA Parkinson's Disease Drugs Share (%), by Country
  • Figure 12. North America Parkinson's Disease Drugs Share (%), by Country
  • Figure 13. Global Parkinson's Disease Drugs: by Type K Units (2015-2020)
  • Figure 14. Global Parkinson's Disease Drugs: by Route of Administration K Units (2015-2020)
  • Figure 15. Global Parkinson's Disease Drugs: by End-users K Units (2015-2020)
  • Figure 16. Global Parkinson's Disease Drugs: by Distribution Channel K Units (2015-2020)
  • Figure 17. South America Parkinson's Disease Drugs Share (%), by Country
  • Figure 18. Asia Pacific Parkinson's Disease Drugs Share (%), by Country
  • Figure 19. Europe Parkinson's Disease Drugs Share (%), by Country
  • Figure 20. MEA Parkinson's Disease Drugs Share (%), by Country
  • Figure 21. North America Parkinson's Disease Drugs Share (%), by Country
  • Figure 22. Global Parkinson's Disease Drugs: by Type USD/Units (2015-2020)
  • Figure 23. Global Parkinson's Disease Drugs share by Players 2020 (%)
  • Figure 24. Global Parkinson's Disease Drugs share by Players (Top 3) 2020(%)
  • Figure 25. Global Parkinson's Disease Drugs share by Players (Top 5) 2020(%)
  • Figure 26. BCG Matrix for key Companies
  • Figure 27. AbbVie (United States Revenue, Net Income and Gross profit
  • Figure 28. AbbVie (United States Revenue: by Geography 2020
  • Figure 29. Merck (United States) Revenue, Net Income and Gross profit
  • Figure 30. Merck (United States) Revenue: by Geography 2020
  • Figure 31. Boehringer Ingelheim (Germany) Revenue, Net Income and Gross profit
  • Figure 32. Boehringer Ingelheim (Germany) Revenue: by Geography 2020
  • Figure 33. Teva (Israel) Revenue, Net Income and Gross profit
  • Figure 34. Teva (Israel) Revenue: by Geography 2020
  • Figure 35. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 36. Novartis AG (Switzerland) Revenue: by Geography 2020
  • Figure 37. GSK (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 38. GSK (United Kingdom) Revenue: by Geography 2020
  • Figure 39. Impax Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 40. Impax Laboratories (United States) Revenue: by Geography 2020
  • Figure 41. Lundbeck (Denmark) Revenue, Net Income and Gross profit
  • Figure 42. Lundbeck (Denmark) Revenue: by Geography 2020
  • Figure 43. UCB (Belgium) Revenue, Net Income and Gross profit
  • Figure 44. UCB (Belgium) Revenue: by Geography 2020
  • Figure 45. Valeant Pharmaceuticals (Canada) Revenue, Net Income and Gross profit
  • Figure 46. Valeant Pharmaceuticals (Canada) Revenue: by Geography 2020
  • Figure 47. Acadia (United States) Revenue, Net Income and Gross profit
  • Figure 48. Acadia (United States) Revenue: by Geography 2020
  • Figure 49. Sun Pharma (India) Revenue, Net Income and Gross profit
  • Figure 50. Sun Pharma (India) Revenue: by Geography 2020
  • Figure 51. Wockhardt (India) Revenue, Net Income and Gross profit
  • Figure 52. Wockhardt (India) Revenue: by Geography 2020
  • Figure 53. Dr. Reddy’s (India) Revenue, Net Income and Gross profit
  • Figure 54. Dr. Reddy’s (India) Revenue: by Geography 2020
  • Figure 55. Intas (India) Revenue, Net Income and Gross profit
  • Figure 56. Intas (India) Revenue: by Geography 2020
  • Figure 57. US WorldMeds (United States) Revenue, Net Income and Gross profit
  • Figure 58. US WorldMeds (United States) Revenue: by Geography 2020
  • Figure 59. Zydus Cadila (India) Revenue, Net Income and Gross profit
  • Figure 60. Zydus Cadila (India) Revenue: by Geography 2020
  • Figure 61. Cipla (India) Revenue, Net Income and Gross profit
  • Figure 62. Cipla (India) Revenue: by Geography 2020
  • Figure 63. Global Parkinson's Disease Drugs: by Type USD Million (2021-2026)
  • Figure 64. Global Parkinson's Disease Drugs: by Route of Administration USD Million (2021-2026)
  • Figure 65. Global Parkinson's Disease Drugs: by End-users USD Million (2021-2026)
  • Figure 66. Global Parkinson's Disease Drugs: by Distribution Channel USD Million (2021-2026)
  • Figure 67. South America Parkinson's Disease Drugs Share (%), by Country
  • Figure 68. Asia Pacific Parkinson's Disease Drugs Share (%), by Country
  • Figure 69. Europe Parkinson's Disease Drugs Share (%), by Country
  • Figure 70. MEA Parkinson's Disease Drugs Share (%), by Country
  • Figure 71. North America Parkinson's Disease Drugs Share (%), by Country
  • Figure 72. Global Parkinson's Disease Drugs: by Type K Units (2021-2026)
  • Figure 73. Global Parkinson's Disease Drugs: by Route of Administration K Units (2021-2026)
  • Figure 74. Global Parkinson's Disease Drugs: by End-users K Units (2021-2026)
  • Figure 75. Global Parkinson's Disease Drugs: by Distribution Channel K Units (2021-2026)
  • Figure 76. South America Parkinson's Disease Drugs Share (%), by Country
  • Figure 77. Asia Pacific Parkinson's Disease Drugs Share (%), by Country
  • Figure 78. Europe Parkinson's Disease Drugs Share (%), by Country
  • Figure 79. MEA Parkinson's Disease Drugs Share (%), by Country
  • Figure 80. North America Parkinson's Disease Drugs Share (%), by Country
  • Figure 81. Global Parkinson's Disease Drugs: by Type USD/Units (2021-2026)
List of companies from research coverage that are profiled in the study
  • AbbVie (United States
  • Merck (United States)
  • Boehringer Ingelheim (Germany)
  • Teva (Israel)
  • Novartis AG (Switzerland)
  • GSK (United Kingdom)
  • Impax Laboratories (United States)
  • Lundbeck (Denmark)
  • UCB (Belgium)
  • Valeant Pharmaceuticals (Canada)
  • Acadia (United States)
  • Sun Pharma (India)
  • Wockhardt (India)
  • Dr. Reddy’s (India)
  • Intas (India)
  • US WorldMeds (United States)
  • Zydus Cadila (India)
  • Cipla (India)
Additional players considered in the study are as follows:
Strides (India) , 1 A Pharma (India) , Upsher-Smith (United States)
Select User Access Type

Key Highlights of Report


Jan 2021 249 Pages 83 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Parkinson's Disease Drugs Market Quantitative research analysis
Global Parkinson's Disease Drugs Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

"Increasing Prevalence of Parkinson's Disease among Elderly People " is seen as one of major growth factors of Parkinson's Disease Drugs Market in years to come.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.

Know More About Global Parkinson's Disease Drugs Market Report?

Have a Query? Click Here

Other Related Reports

Antitumor Antibiotics Comprehensive Study by Type (Anthracyclines (doxorubicin, daunorubicin, epirubicin, mitoxantrone, and idarubicin), Chromomycin (dactinomycin and plicamycin), Miscellaneous (mito...
$ 3650
Tourette Syndrome Treatment Comprehensive Study by Treatment (Medication, Therapy), Distribution Channel (Online, Offline), Medication (Botulinum (Botox) injections, ADHD medications, Central adrener...
$ 3750
Varicella Live Vaccine Comprehensive Study by Type (Single-antigen Vaccine, Combined Vaccine), Application (Chickenpox Immunization, Herpes Zoster Immunization, MMRV Immunization), End-user (Hospital...
$ 3650
Zinc Deficiency Treatment Comprehensive Study by Type (Dietary Supplements, Oral Repletion Therapy), Application (Malnutrition, Anorexia, Oral Ulcers, Acne), Route of Administration (Oral Solids, Sy...
$ 3750
Moderna Vaccine Comprehensive Study by End User (Laboratories, Hospitals, Diagnostic Centers and Clinics, Research Institutes, Others) Players and Region - Global Market Outlook to 2030
$ 3500
Alverine Citrate Comprehensive Study by Administration (Oral, Injection), Level (Mild, Moderate, Severe), End User (Adult, Children), Capsules (60 MG, 120 Mg, Others (300 Mg)) Players and Region - ...
$ 3500